Agios Pharmaceuticals
AGIO
201 hedge funds and large institutions have $4.06B invested in Agios Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 80 increasing their positions, 50 reducing their positions, and 32 closing their positions.
106% more call options, than puts
Call options by funds: $55M | Put options by funds: $26.8M
60% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 50
52% more capital invested
Capital invested by funds: $2.66B → $4.06B (+$1.4B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 32
3.17% more ownership
Funds ownership: 99.8% → 102.97% (+3.2%)
3% more funds holding
Funds holding: 196 → 201 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.2M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$24.7M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20M |
| 4 |
Goldman Sachs
New York
|
+$18.7M |
| 5 |
Alkeon Capital Management
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$10.6M |
| 2 |
Millennium Management
New York
|
-$9.96M |
| 3 |
Neuberger Berman Group
New York
|
-$9.78M |
| 4 |
D.E. Shaw & Co
New York
|
-$6.45M |
| 5 |
CC
Casdin Capital
New York
|
-$6.41M |
AGIO Hedge Fund Activity: Q1 2019 in Review
201 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2019, worth a combined $4.06B — up 52% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AGIO positions and 32 closed out — a net gain of 6 holders — while 80 added to existing stakes and 50 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $26.2M. The largest seller was Two Sigma Investments, exiting entirely with an estimated $10.6M sold.
- 201 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2019, up from 196 in Q4 2018.
- Funds reported $4.06B of Agios Pharmaceuticals stock for Q1 2019, up 52% quarter-over-quarter.
- 38 funds opened new Agios Pharmaceuticals positions in Q1 2019 and 32 closed out, a net change of +6 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $26.2M added.
- The largest Agios Pharmaceuticals seller in Q1 2019 was Two Sigma Investments, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2019.